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ABSTRACT 
Perception of asthma can affect the patient's self-management and outcome treatment. The outcome is not only 
determined by symptoms, but also by illness perception. Omega-3 in fish oil has a potential effect on asthma. The 
study aimed to determine the effect of illness perception on improvement symptoms with fish oil, measured by 
Asthma-Control-Test (ACT). This research was pre-post test design and purposive sampling, used 1 g daily fish oil 
then followed-up after 4 weeks, conducted in March 2017–January 2018. The relationship between ACT value and 
illness perception using chi square test. The study sample consisted of 26 patients. The effectiveness of omega-3 
showed that there was significant difference of symptoms after the therapy. It can be concluded there was effect of 
illness perception relationships related to symptoms. Most of the highest illness perception regarding symptoms and 
symptoms related to asthma respondents experienced on the individual values, related to symptoms are fixed. While 
the influence of illness perception on symptoms that got significant results was how long the asthma suffered, and the 
illness perception on causes of asthma that were significant to changes in asthma symptoms. Omega-3 fish oil was 
effective in improving asthma symptoms, but the influence of illness perception must also be a concern.
INTRODUCTION
Asthma is a heterogeneous disease, characterized by 
chronic inflammation of the airways that involves inflammatory 
cells that cause episodic symptoms, such as wheezing, shortness 
of breath, chest tightness, and cough. The number of asthma 
sufferers in the world reached 334 million. Asthma prevalence 
in various countries ranges from 1% to 18% of the population 
(Global Initiative for Asthma, 2017). In Indonesia, especially in the 
province of East Java, the prevalence of asthma has reached 5.1%, 
and it is estimated that the prevalence of asthma will continue 
to increase with increasing age up to 5.6% in the age range of 
15–24 years (Badan Penelitian dan Pengembangan Kesehatan 
Departemen Kesehatan Republik Indonesia, 2013). Asthma in 
Indonesia is not known with certainty, but an estimated 2%–5% of 
Indonesia's population suffer from asthma (Oemiati et al., 2010). 
Symptoms of asthma can be mild and do not interfere with 
activity but can also be permanent. Symptoms also vary because 
of the limited degree of asthma air flow (Krishnan et al., 2012). 
Symptoms of asthma can have a negative impact on quality of life 
because they cause limited daily activities, affect psychologically, 
and the patient's social life that affects the education and career of 
the patient (Hossny et al., 2017). 
The changes in asthma symptoms can be observed using 
a questionnaire that focuses on changes in asthma symptoms, such 
as the Asthma Control Test (ACT) (Moamary et al., 2012) which 
has been widely used in monitoring asthma treatment. Asthma 
therapy aims to prevent/ relieve symptoms to reduce the risk of 
acute attacks and tissue damage, to improve the quality of life 
(Braido, 2013; Global Initiative for Asthma, 2017).
Synthetic drugs can cause adverse drug reaction (ADR). 
During this time, asthma treatment focuses on therapy with long-term 
synthetic drugs, which can cause problems such as: aminophylline 
has narrow therapeutic range that risks causing ADR (Barnes, 
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2010; Lorensia et al., 2012; Tyagi et al., 2008), long-acting beta-
agonist monotherapy could cause aggravate asthma exacerbations 
(Billington et al., 2017), or inhaled corticosteroids caused 
oropharyngeal candidiasis (Global Initiative for Asthma, 2017).
Omega-3 include of docosahexaenoic acid (DHA) and 
eicosapentaenoic fatty acids (EPA), are polyunsaturated found 
mainly in fish oil (Mickleborough and Lindley, 2014). Omega-3 
has beneficial effects on chronic inflammatory diseases, including 
chronic obstructive pulmonary disease and asthma (D’Auria et al., 
2014; Miyata and Arita, 2015). Research shows that consumption 
of fish at least 2–3 times/week can increase level of omega-3 
(British Dietetic Association, 2017), thereby reducing the risk of 
asthma (Rosenkranz et al., 2012). Anti-inflammatory effects on 
EPA is competitive with arachidonic, has potential effect to reduce 
respiratory inflammation and bronchoconstriction in asthma (Han 
et al., 2015; Thien et al., 2002). Drug effects are individual, and 
asthma research is now beginning to pay attention to genetic 
influences in the treatment (Davis et al., 2015; Fotenko, 2011; 
Ortega et al., 2015). Previous studies have been carried out in 
Caucasian races (D’Auria et al., 2014; Mickleborough and Lindley, 
2014; Miyata and Arita, 2015), but there is no strong evidence on 
Indonesian society as a different Asian race than abroad.
Previous research by Lorensia and Lisiska (2011) states that 
perceptions of asthma can affect patients' self-management behavior, 
thus affecting their treatment outcomes. The results of asthma therapy 
are not only determined by symptomps or lung function, but also the 
illness perception that patient has, is the patient's subjective beliefs 
and emotional response to the disease. Many studies have shown 
that the perception of disease has a large share of therapeutic results, 
so the conclusion that disease perception that reflects the patient's 
personal control of the disease for positive results is asthma control 
(Kaptein et al., 2010). Research on the role of illness perception in 
medical conditions has grown rapidly in recent years. This is the 
beginning of the development of a scale to measure disease beliefs, 
such as the illness perception questionnaire (IPQ), and then by strong 
associations can be found a relationship between patient perceptions 
of their disease and the results of their behavior. Chronic diseases 
like asthma are quite a burden on patients and have a significant 
impact on their quality of life. Illness perception has been shown to 
have an important association with outcomes in various acute and 
chronic diseases (Petrie et al., 2007). The study aims to see illness 
perception toward their asthma by using the IPQ and see the effect of 
omega-3 fish oil on asthma control measured using the ACT.
METHODS
Design study
This study used a pre-post test design method. This 
study used data collection techniques with the ACT questionnaire 
to see the clinical symptoms of asthma. Each research sample was 
given fish oil. The intervention provided was a fish oil product 
circulating in Indonesia. This fish oil was given to patients at once 
daily doses, then followed up after 4 weeks. The recommended 
dose of fish oil containing omega-3 was 1–5.4 g per day (Calder, 
2012), Hence, in this study, fish oil with a dose of 1.0 g was chosen. 
Ethical committee approval
Ethics testing has been conducted at the University of 
Surabaya with No. 011/KE/I/2017.
Variable research and the measuring instrument
The independent variable of this study was fish oil, while 
the dependent variable of this study was symptoms of asthma and 
pulmonary function, with controlled variables in accordance with 
inclusion and exclusion criteria.
Symptoms of asthma
Asthma symptoms were measured using the ACT 
questionnaire. ACT is a specific instrument in assessing asthma 
control in chronic asthma patients. Consisting of five questions 
that included limited activity, long periods of tightness, symptoms 
of asthma at night, frequency of use of reliever drugs, and level of 
asthma control that was calculated for 4 weeks. Each question was 
given a choice of answers to five-Likert scale (Global Initiative 
for Asthma. 2017; Moamary et al., 2012). Asthma symptoms were 
measured twice, namely: at week 0 (before giving intervention) 
and at week 4 (after giving intervention).
The initials that will be used as follows:
ACT0 :  ACT value at week 0, ie before getting fish oil therapy 
containing omega-3
ACT4 :  ACT value at week 4, which is after receiving fish oil 
therapy containing omega-3 for 4 weeks (1 month)
Illness perception
Illness perceptions were formed from initial experiences 
with episodes related to disease and how to respond to pain and 
discomfort from other people and the environment (Kaptein et al., 
2010). Measurement of illness perception could be described by 
five dimensions in cognitive representation of illness, including: 
(1) Identify (patient label used to describe illness and symptoms 
they experience as part of a disease); (2) Consequences (expected 
effects and outcomes of illness); (3) Cause (personal idea about the 
cause of the disease); (4) Timeline (how long the patient believes 
that the disease will last); and (5) Cure or Control (explains what 
patients believe that they can recover or recover from their illness) 
(Calder, 2012; Tiemensma et al., 2016).
Population and sample
The population of this study were adult asthma patients 
(>18 years) in Surabaya. The sample (subject) of the study were 
collected by purposive sampling that fulfill the criteria, namely 
(inclusion and exclusion criteria): not having chronic diseases 
that could affect respiratory function (such as: chronic respiratory 
disease, heart disease, and chronic renal failure); Do not smoke or 
consume alcohol; and not using routine asthma medication.
The sample size in this study was at least 26 people. 
Sample size calculation method uses equations:
=n
Z
2
.P .Q
d
2
Z = 1.96
P =  0.017 (Badan Penelitian dan Pengembangan Kesehatan 
Departemen Kesehatan Republik Indonesia, 2013)
Q = 1−P = 1–0.0262 = 0.983
d = 0.05
Then, the study sample size (n) is minimal for each 
group in this study was 25.67 ~ 26 people.
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Data analysis method
Asthma symptoms would be tested for normality of data 
distribution using the Shapiro–Wilk test. If the p value > 0.05, it 
can be concluded that the data is normally normal distributed and 
then followed by paired t-test to determine the effect of illness 
perception on and clinical symptoms. The relationship between 
ACT value and illness perception using chi square test.
RESULTS AND DISCUSSION
Data collection was conducted in March 2017–January 
2018. The data obtained in this study were obtained illness 
perception and ACT questionnaire that given at before and after 
fish oil intervention. Of the number of subjects initially involved 
the research, there were two peoples who were dropped out due 
to allergies to fish oil (red spots appeared on the face after the 
second week of getting fish oil therapy) and others because he had 
to going out of the city so cannot take therapy again. Until the end 
of the study, there were 26 respondents who followed the complete 
research series.
Respondents in this study were grouped according to 
gender, age, and treatment history (Table 1). The highest gender 
was women (73%) compared to men (27%). The most age of this 
study was at the stage of late adolescence (17–25 years) (96.15%). 
For the treatment, history of many respondents using inhaled short 
acting beta-2 agonists (26.31%) in step 1 (Global Initiative for 
Asthma, 2017) (Table 1).
The effectiveness data of omega-3 fish oil using ACT 
questionnaire showed that there was significant difference 
[p value (0.041) < 0.05] of symptoms based on ACT value before 
[normality test: p (0.558) > 0.05] and after therapy [normality test: 
p (0.460) >0.05], used analysis of variance one-way test.
In Table 2, the influence of illness perception related 
to the symptoms of the ACT value. Obtained the results of the 
p< 0.05, Ho was rejected so there was the influence of illusion 
perception relations related to the significant symptoms of the 
ACT value. 
Illness perception will affect asthma patients’ behaviour 
and self-management from the disease. This data can inform health 
care providers about patients' psychosocial responses to their 
asthma; they are responsive to the changes in clinical meetings 
or through self-management intervention training. Exploring the 
patient's illness perception, therefore, is an important component 
of good clinical care (Kaptein et al., 2010). One of the factors 
that influence self-management is illness perception which is a 
cognitive picture of the patient about his illness (Gibbons et al., 
2013). This picture is identified through five dimensions, namely, 
identity, consequences, cause of illness, timeline, and cure or 
control (Kaptein et al., 2010; Morris et al., 2002; Petrie et al., 
2007). By knowing one's perception of the disease, it can be 
done by providing education and further information to patients. 
In addition, efforts can be made to develop strategies for health 
approaches and promotion that are good for reducing the number 
of patients who are exposed to asthma attacks and participating in 
improving the quality of life of patients.
In Table 3, most of the highest illness perception 
regarding symptoms and symptoms related to asthma respondents 
experienced on the individual values, related to symptoms are 
fixed, namely, questions number 1 (7 respondents), number 
2 (9 respondents), number 3 (10 respondents), number 4 
(9 respondents), while in question number 5, the highest value 
rises (11 respondent). In the symptom associated with asthma, 
the highest value is still in question number 1 (6 respondents), 
number 2 (8 respondents), number 3 (8 respondents), number 4 
(7 respondents), while in question number 5 is up (9 respondents).
The influence of illness perception on asthma on ACT 
values that got significant results was B2, namely, how long the 
asthma suffered by patients with a p value < 0.05 (0.018), Ho was 
rejected then there is a significant difference between the influence 
Table 1. Frequency distribution of research subject character.
Characteristics Frequency  (n = 26)
Percentage  
(%)
Gender Man 7 27.00
Woman 19 73.00
Age (years) Late teenagers (17–25) 25 96.15
Early adult (26–35) 1 3.85
Late adult (36–45) 0 0
Medical 
history
Oral short-acting beta-2 agonist 8 21.05
Inhaled short-acting beta-2 agonist 10 26.31
Oxygen 1 2.63
Not using any medication 3 7.89
ral corticosteroids (only used when 
symptoms worsen)
1 2.63
Metilsantin oral (only used when 
symptoms worsen)
3 11.53
Other 8 21.05
Step treatment 
for asthma (1)
Step 1 26 100
Table 2. Effect of illness perception regarding symptoms and symptoms related 
to asthma experienced by respondents on the ACT value.
Illness perception
Number 
of asthma 
symptoms
Change in ACT Value
p valueDecrease 
(n = 5)
Increase 
(n = 15)
Fixed  
(n = 6)
Symptoms experienced by 
patients
Four highest 
symptoms:A4,A6,A9,A12
0 0 0 1 0.018
1 0 0 0
2 0 1 1
3 3 4 0
4 2 10 4
Total 26
Relationship with asthma 
symptoms experienced by 
patients
Four highest 
symptoms:A4,A6,A9,A12
0 0 0 0 0.329
1 0 0 0
2 1 2 1
3 2 6 1
4 2 7 4
Total 26
p > 0.05, Ho is accepted meaning there is no significant difference,
p <0.05, Ho is rejected meaning there is a significant difference
A4 = difficulty breathing/tightness, A9 = when breathing is sound (wheezing), 
A12 = difficulty sleeping, A6 = tired, Increase = there is an increase in the change in ACT 
value between before and after being given fish oil, Fixed = no change in ACT value 
between before and after fish oil was given, Decrease = there was a decrease in the change 
in ACT value between before and after fish oil was given.
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of illness perception related to how long the disease asthma 
suffered from ACT values (Table 4).
In Table 5, the influence of illness perception on causes 
of asthma on the ACT value. The results of C1–C17 p value > 0.05, 
Ho was accepted so there was no significant difference in static. 
Except for C3 with a p value < 0.05, Ho was rejected, so the 
relationship between the causes of asthma and the ACT value was 
statistically significant.
Patient perception is a cognitive picture of patients with 
their disease by identifying five dimensions, namely, identity, 
consequences, cause of illness, timeline, and cure or control. 
These five dimensions are as follows:
Patient perception regarding labels/symptoms used to describe 
the disease (identity)
The results showed that subjective perceptions of the 
symptoms of the disease were mostly experienced by asthma 
patients: shortness of breath (92.31%), wheezing (92.31%), 
fatigue (80.77%), and insomnia (76, 92%). This is consistent with 
asthma symptoms that do occur. Whistling sound is caused by a 
disturbance in the respiratory tract or excessive mucus production. 
If there is difficulty in breathing, then the body's cells experience 
a lack of O2 supply, which can cause difficulty sleeping or waking 
at night, while also causing the body to become tired. While sore 
throat, nausea, abdominal pain, joint stiffness, eye pain, headache, 
dizziness, and weight loss are symptoms that are not related to 
asthma. However, the possibility of these symptoms can be 
caused by side effects of drugs used by the patients (Shaharum 
et al., 2012).
Patient perception regarding the impact and results of diseases 
(consequences)
Most respondents (50.00%) answered that the asthma 
affects activity. In reality, asthma patients do have limitations in 
their activities. Therefore, if it is known what activities can cause 
asthma, patients should be given counseling to take the medicine 
first as a prevention of the occurrence of an asthma attack (Global 
Initiative for Asthma, 2017).
The patient's perception of the cause of the disease  
(cause of illness)
The three highest factors causing their asthma in a row 
are hereditary factors, viruses, germs, and bacteria, and decreased 
immunity. Hereditary/genetic factors are a family history of 
patients who have had asthma. Heredity/ genetics is indeed one of 
the causes of dominant asthma. Some viruses that cause infections, 
such as Rhinovirus, have a relationship to recurrence of wheezing 
in childhood. But, the reality of wheezing in adulthood occurs 
because of various conditions and not all wheezing conditions 
in adulthood are an indication of asthma (Global Initiative for 
Asthma, 2017).
Patient perception of how long asthma will last (timeline)
Asthma does not recognize the word “cured,” because it 
cannot be cured and can appear at any time. Symptoms of asthma 
can last forever (Global Initiative for Asthma, 2017). The results 
showed that only a few patients (8 of 26 people) who knew asthma 
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Table 4. Effects of illness perception on asthma on ACT values.
No. Perceptions related to asthma illness perception Answer category
Change in ACT value
Total p valueDecrease 
(n = 5)
Increase 
(n = 15)
Fixed  
(n = 6)
B1 How much asthma affects 
activity
Not affect at all 0 0 0 0 0.210
Little influence 3 3 0 6
Doubtful 0 1 0 1
Enough Affect 1 7 5 13
Very influential 1 4 1 6
Total 26 26
B2 How long will asthma be 
suffered by the patient
Just a few days 0 1 1 2 0.018
Several months 1 0 0 1
Doubtful 3 2 3 8
Several years 1 5 1 7
Forever 0 7 1 8
Total 26 26
B3 The patient feels that his 
asthma is
Not controlled at all 0 3 0 3 0.155
Little controlled 1 5 0 6
Doubtful 1 2 2 5
Controlled 3 4 4 11
Perfect control 0 1 0 1
Total 26 26
B4 Treatment done Not helpful 0 0 0 0 0.155
A little help 0 4 1 5
Doubtful 2 3 0 5
Help 3 7 4 14
Very helpful 0 1 1 2
Total 26 26
B5 How often do patients 
experience asthma 
symptoms
Never 0 1 1 2 0.155
1–2× a month 1 1 0 2
Don't know (suddenly appears) 4 11 5 20
1–2× a week 0 2 0 2
Every day 0 0 0 0
Total 26 26
B6 Patients feel anxiety/
anxiety about asthma Not at all worried 0 1 0 1
0.155
A little worried 2 7 3 12
Doubtful 0 1 2 3
Worry 3 5 1 9
Very worried 0 1 0 1
Total 26 26
B7 Understanding of asthma
Do not understand 1 1 0 2 0.155
Understand a little 0 4 1 5
Doubtful 0 3 1 4
Understand 4 6 4 14
Really understand 0 1 0 1
Total 26 26
B8 Asthma affects patient 
emotions Does not make me emotional 1 5 0 6
0.155
A little emotion 0 3 1 4
Doubtful 2 2 1 5
Emotion 2 3 3 8
Very emotional 0 2 1 3
Total 26 26
(continued)
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No. Perceptions related to asthma illness perception Answer category
Change in ACT value
Total p valueDecrease 
(n = 5)
Increase 
(n = 15)
Fixed  
(n = 6)
B9 Asthma affects patient 
finance
Not affect at all 3 5 2 10 0.155
Little influence 0 6 2 8
Doubtful 0 1 1 2
Influence 1 3 1 5
Very influential 1 0 0 1
Total 26 26
p > 0.05, Ho is accepted meaning there is no significant difference, 
p <0.05, Ho is rejected meaning there is a significant difference
Increase = there is an increase in the change in ACT value between before and after being given fish oil, Fixed = no change in ACT value between 
before and after fish oil was given, Decrease = there was a decrease in the change in ACT value between before and after fish oil was given.
Table 4. (continued)
Table 5. Effects of illness perception on causes of asthma on ACT values.
No. Causes of asthma Answer category
Change in ACT value
Total p valueDecrease 
(n = 5)
Increase  
(n = 15)
Fixed  
(n = 6)
C1 Stressful or anxious SD 0 4 0 4 0.379
D 2 1 0 3
Do 0 1 1 2
A 1 7 3 11
SA 2 2 2 6
Total 26 26
C2 Descent / genetic SD 0 2 0 2 0.379
D 1 1 0 2
Do 0 1 0 1
A 1 4 3 8
SA 3 7 3 13
Total 26 26
C3 Germs, viruses, 
infections
SD 0 0 0 0 0.031
D 0 1 0 1
Do 2 5 0 7
A 3 5 4 12
SA 0 4 2 6
Total 26 26
C4 Pattern or eating habits SD 0 1 0 1 0.618
D 0 2 1 3
Do 1 5 3 9
A 3 4 1 8
SA 1 3 1 5
Total 26 26
C5 Bad luck SD 2 3 1 6 0.115
D 2 6 1 9
Do 0 6 3 9
A 1 0 1 2
SA 0 0 0 0
Total 26 26
(continued)
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No. Causes of asthma Answer category
Change in ACT value
Total p valueDecrease 
(n = 5)
Increase  
(n = 15)
Fixed  
(n = 6)
C6 Bad care in the past SD 2 3 0 5 0.578
D 3 7 2 12
Do 0 4 3 7
A 0 1 0 1
SA 0 0 1 1
Total 26 26
C7 Environmental pollution SD 0 0 0 0 0.473
D 1 0 0 1
Do 0 1 0 1
A 3 11 4 18
SA 1 3 2 6
Total 26 26
C8 My own behavior SD 0 0 0 0 0.719
D 0 3 1 4
Do 1 4 2 7
A 3 7 2 12
SA 1 1 1 3
Total 26 26
C9 Always think negatively SD 1 2 0 3 0.271
D 3 8 1 12
Do 0 4 3 7
A 0 1 1 2
SA 1 0 1 2
Total 26 26
C10 Family problems SD 3 3 1 7 0.465
D 1 6 1 8
Do 1 4 1 6
A 0 1 2 3
SA 0 1 1 2
Total 26 26
C11 Too much work SD 0 2 0 2 0.271
D 1 2 0 3
Do 1 4 3 8
A 2 4 2 8
SA 1 3 1 5
Total 26 26
C12 Emotional feeling SD 0 3 0 3 0.344
D 2 2 0 4
Do 1 4 2 7
A 2 4 4 10
SA 0 2 0 2
Total 26 26
C13 Aging / increasing age SD 2 3 2 7 0.640
D 2 7 1 10
Do 0 4 3 7
A 1 1 0 2
SA 0 0 0 0
Total 26 26
Table 5. continued
(continued)
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would last forever. Many research subjects do not know that 
asthma can occur at any time and unexpected. 
Patient perceptions regarding medication that can help disease 
(cure or control)
The results showed that most patients (11 of 26 patients) 
said their asthma had been controlled. Subjects argued that the 
treatment used helped overcome the asthma attack (14 of 26 
people). This is one of the characteristics of controlled asthma 
(Global Initiative for Asthma, 2017). 
Fish oil containing omega 3 consisting of EPA and 
DHA suppresses the production of arachidonic acid through the 
arachidonate 5-lipoxygenase (ALOX5) pathway. Arachidonic 
acid is a substrate for the synthesis of eicosanoids which produces 
an inflammatory mediator consisting of cysteinyl leukotriene, 
prostaglandin, and thromboxane. This mediator is involved in the 
bronchoconstriction process and increases mucus in the respiratory 
tract in asthma patients. EPA-enriched fish oil can inhibit the 
production of leukotriene C4 which is competitive with arachidonic 
acid which functions as the ALOX5 substrate. EPA can also suppress 
allergic responses in asthma by inhibiting arachidonic acid that 
produces leukotrienes. Leukotrienes and prostaglandin E2 contribute 
to the formation of immunoglobulin E, an antibody that plays a role 
in the allergic response. This usually increases in asthma patients 
(Ogden, 2012).
No. Causes of asthma Answer category
Change in ACT value
Total p valueDecrease 
(n = 5)
Increase  
(n = 15)
Fixed  
(n = 6)
C14 Alcohol consumption SD 0 6 2 8 0.144
D 1 3 0 4
Do 2 4 4 10
A 2 2 0 4
SA 0 0 0 0
Total 26 26
C15 Smoke SD 0 5 1 6 0,473
D 1 1 0 2
Do 1 1 0 2
A 1 4 2 7
SA 2 4 3 9
Total 26 26
C16 Due to injury / accident SD 2 5 2 9 0.463
D 2 6 1 9
Do 1 4 3 8
A 0 0 0 0
SA 0 0 0 0
Total 26 26
C17 Decreased immunity SD 0 0 0 0 0.666
D 0 0 0 0
Do 2 3 2 7
A 3 7 3 13
SA 0 5 1 6
Total 26 26
No.1 = ACT questions limitations of respondent activities, No.2 = ACT questions frequency of respiratory shortness of respondents, No. 3 
= ACT questions arise symptoms of asthma at night or respondent morning, No. 4 = ACT questions frequency of use of asthma medicines 
respondents, No. 5 = ACT questions level of asthma control, Increase = there is an increase in the change in ACT value between before and 
after being given fish oil, Fixed = no change in ACT value between before and after fish oil was given, Decrease =. there was a decrease in 
the change in ACT value between before and after fish oil was given, SD = strongly disagree, D = disagree, Do = doubtfully, A = agree, SA = 
strongly agree.
p > 0.05, Ho is accepted meaning there is no significant difference.
p < 0.05, Ho is rejected meaning there is a significant difference.
Table 5. continued
Table 6. Effects of illness perception on asthma on ACT values.
No. Answer Category
Change in ACT value
Decrease Decrease Decrease
1 Descent/genetic (C2) 4 7 5
2 Germ, virusi, infection (C3) 1 4 2
3 Decreased body immunity (C17) 0 5 1
Increase = there is an increase in the change in ACT value between before and after being 
given fish oil. Fixed = no change in ACT value between before and after fish oil was given. 
Decreas = there was a decrease in the change in ACT value between before and after fish 
oil was given.
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In Table 6, about the influence of Illness Perception 
related to asthma on the ACT value, the highest answer was on 
offspring / genetic and ACT value rose by seven respondents.
In conducting research, there are still weaknesses and 
shortcomings, although researchers have tried their best to make 
research results perfect.
Researchers realize that the limitations of research include:
1. The inclusion criteria of respondents such as heart 
and kidney history data were not obtained accurately. Because 
when the respondent said that there was no history of the heart and 
kidneys was not supported by the results of the doctor's checking 
first using electrocardiogram.
2. The type of fish oil used in this study is fish oil 
originating from abroad. Researchers use this type of fish oil 
because the dose is in accordance with the desired dose of fish 
oil which is 1.0 g. Therefore, respondents feel less comfortable 
consuming fish oil which is considered quite large because some 
respondents commented on the soft capsule which is quite large.
CONCLUSION
The effectiveness data of omega-3 fish oil using ACT 
questionnaire showed that there was significant difference (p value 
(0.041) <0.05) of symptoms based on before and after therapy. 
There was an effect of illness perception relationships related 
to asthma symptoms. Most of the highest illness perception 
regarding symptoms and symptoms related to asthma respondents 
experienced on the individual values, related to symptoms are 
fixed. While the influence of illness perception on asthma on 
ACT values that got significant results was how long the asthma 
suffered, and the illness perception on causes of asthma that were 
significant to changes in asthma symptoms.
LIST OF ABBREVIATIONS 
ACT Asthma control test
ADR Adverse drug reaction
ALOX5 Arachidonate 5-lipoxygenase
DHA Docosahexaenoic acid
EPA Eicosapentaenoic fatty acids 
IPQ Illness perception questionnaire
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